NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

$126.17

+1.01 (+0.81%)

(As of 06/5/2023 ET)

Compare

Today's Range: $125.43
▼
$127.62
50-Day Range: $120.20
▼
$157.19
52-Week Range: $61.28
▼
$159.89

Volume: 1.04 million shs
Average Volume: 1.51 million shs
Market Capitalization: $11.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $168.76

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.94 Rating Score
Upside/Downside: 33.8% Upside
$168.76 Price Target
Short Interest: Healthy
4.03% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: -0.20
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($10.88) to $1.84 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

59th out of 985 stocks

Pharmaceutical Preparations Industry

22nd out of 486 stocks

4.5

Analyst's Opinion

Consensus Rating
Sarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $168.76, Sarepta Therapeutics has a forecasted upside of 33.8% from its current price of $126.17.
Amount of Analyst Coverage
Sarepta Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
4.03% of the outstanding shares of Sarepta Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sarepta Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sarepta Therapeutics has recently decreased by 8.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sarepta Therapeutics does not currently pay a dividend.
Dividend Growth
Sarepta Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Sarepta Therapeutics is -1.65.

1.6

News and Social Media Coverage

News Sentiment
Sarepta Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 7 articles on an average week.
Search Interest
36 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 16% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Sarepta Therapeutics is held by insiders.
Percentage Held by Institutions
87.31% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sarepta Therapeutics are expected to grow in the coming year, from ($10.88) to $1.84 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sarepta Therapeutics is -9.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sarepta Therapeutics is -9.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sarepta Therapeutics has a P/B Ratio of 28.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (SRPT)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

May 16, 2023 | marketbeat.com

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy (SRPT)

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.

June 5, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

June 1, 2023 | finance.yahoo.com

Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?

June 1, 2023 | msn.com

Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?

May 30, 2023 | msn.com

Evercore ISI Group Maintains Sarepta Therapeutics (SRPT) Outperform Recommendation

May 30, 2023 | americanbankingnews.com

Evercore ISI Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $151.00

May 30, 2023 | americanbankingnews.com

William Blair Comments on Sarepta Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:SRPT)

June 5, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 27, 2023 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) PT Lowered to $141.00

May 26, 2023 | msn.com

Oppenheimer Reiterates Sarepta Therapeutics (SRPT) Outperform Recommendation

May 26, 2023 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down on Analyst Downgrade

May 24, 2023 | msn.com

Sarepta Tumbles as FDA Delays Duchenne Gene Therapy Decision

May 24, 2023 | markets.businessinsider.com

Sarepta Therapeutics Updates Of BLA For Sarepta's Duchenne Muscular Dystrophy Drug Candidate

May 24, 2023 | msn.com

Sarepta Plunges as FDA Requires More Time for Drug Review

May 24, 2023 | finance.yahoo.com

FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks

May 24, 2023 | finance.yahoo.com

Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy

May 24, 2023 | finance.yahoo.com

Why Shares of Sarepta Therapeutics Are Dropping Wednesday

May 24, 2023 | reuters.com

FDA defers decision for Sarepta's gene therapy to June 22 from May 29

May 24, 2023 | msn.com

Sarepta says FDA needs more time to review muscular dystrophy drug

May 24, 2023 | finance.yahoo.com

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001

May 24, 2023 | finance.yahoo.com

UPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29

May 23, 2023 | seekingalpha.com

Buy Sarepta Therapeutics For A Likely Positive FDA Decision Date

May 23, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tandem Diabetes Care (TNDM), Sarepta Therapeutics (SRPT) and Immunovant (IMVT)

May 21, 2023 | msn.com

Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

May 21, 2023 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at StockNews.com

May 20, 2023 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Given New $218.00 Price Target at Royal Bank of Canada

See More Headlines

SRPT Price History

30 days | 90 days | 365 days | Advanced Chart

SRPT Company Calendar

Last Earnings: 5/02/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SRPT
Previous Symbol: NASDAQ:AVII
CUSIP: N/A
CIK: 873303
Web: www.sareptatherapeutics.com
Phone: (617) 274-4000
Fax: 425-354-5038
Employees: 1,162
Year Founded: 1980

Price Target and Rating

Average Stock Price Forecast: $168.76
High Stock Price Forecast: $218.00
Low Stock Price Forecast: $122.00
Forecasted Upside/Downside: +33.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.94
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($12.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-703,490,000.00
Net Margins: -114.30%
Pretax Margin: -112.59%
Return on Equity: -128.64%
Return on Assets: -23.50%

Debt

Debt-to-Equity Ratio: 1.73
Current Ratio: 4.63
Quick Ratio: 4.26

Sales & Book Value

Annual Sales: $933.01 million
Price / Sales: 12.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.39 per share
Price / Book: 28.72

Miscellaneous

Outstanding Shares: 93,150,000
Free Float: 86,256,000
Market Cap: $11.74 billion
Optionable: Optionable
Beta: 1.01

Social Links

Key Executives

Douglas S. Ingram
President, Chief Executive Officer & Director

Ian M. Estepan
Executive VP, Chief Financial & Accounting Officer

Louise Rodino-Klapac
Chief Scientific Officer & Executive VP

Bilal Arif
Chief Technical Operations Officer & Executive VP

Diane Berry
EVP, Chief Global Policy & Advocacy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.
What is Sarepta Therapeutics' stock price forecast for 2023?: 16 Wall Street analysts have issued 1 year price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $218.00. On average, they predict the company's stock price to reach $168.76 in the next year. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.
How have SRPT shares performed in 2023?: Sarepta Therapeutics' stock was trading at $129.58 at the start of the year. Since then, SRPT stock has decreased by 2.7% and is now trading at $126.07.
View the best growth stocks for 2023 here.
When is Sarepta Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SRPT earnings forecast.
How were Sarepta Therapeutics' earnings last quarter?: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.46) by $0.49. The biotechnology company earned $253.50 million during the quarter, compared to analysts' expectations of $241.47 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 128.64% and a negative net margin of 114.30%. The business's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.20) EPS.
What ETFs hold Sarepta Therapeutics' stock?: ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), American Century Mid Cap Growth Impact (MID), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), Invesco Dynamic Biotechnology & Genome ETF (PBE) and AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ).
What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?: 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sarepta Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?: Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
Who are Sarepta Therapeutics' major shareholders?: Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.67%), Wellington Management Group LLP (3.15%), Bank of New York Mellon Corp (2.06%), State Street Corp (1.90%), Geode Capital Management LLC (1.35%) and Pictet Asset Management SA (1.30%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends.
How do I buy shares of Sarepta Therapeutics?: Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sarepta Therapeutics' stock price today?: One share of SRPT stock can currently be purchased for approximately $126.07.
How much money does Sarepta Therapeutics make?: Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $11.74 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($12.69) on an earnings per share basis.
How many employees does Sarepta Therapeutics have?: The company employs 1,162 workers across the globe.
Does Sarepta Therapeutics have any subsidiaries?: The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?: Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

Sarepta Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

SRPT Stock News Headlines

SRPT Price History

SRPT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SRPT Stock - Frequently Asked Questions

Overall MarketRank^™